Production (Stage)
BioRestorative Therapies, Inc.
BRTX
$1.66
$0.063.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 161.54% | 175.03% | 189.55% | 35.49% | 10.66% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 161.54% | 175.03% | 189.55% | 35.49% | 10.66% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 140.87% | 155.83% | 170.58% | 30.43% | 10.66% |
| SG&A Expenses | -32.63% | -41.76% | -41.81% | -39.25% | -37.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.71% | -22.19% | -25.87% | -28.60% | -30.93% |
| Operating Income | 9.58% | 24.08% | 27.55% | 29.05% | 31.21% |
| Income Before Tax | -121.20% | 13.81% | -34.20% | 77.20% | 64.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -121.20% | 13.81% | -34.20% | 77.20% | 64.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -121.20% | 13.81% | -34.20% | 77.20% | 64.90% |
| EBIT | 9.58% | 24.08% | 27.55% | 29.05% | 31.21% |
| EBITDA | 9.91% | 24.50% | 27.97% | 29.46% | 31.60% |
| EPS Basic | -17.60% | 59.07% | 30.80% | 93.73% | 70.50% |
| Normalized Basic EPS | -0.74% | 66.48% | 30.80% | 93.73% | 70.50% |
| EPS Diluted | -17.58% | 58.97% | 30.74% | 93.57% | 70.42% |
| Normalized Diluted EPS | -0.74% | 66.48% | 30.80% | 93.73% | 70.50% |
| Average Basic Shares Outstanding | 65.15% | 84.08% | 74.29% | 61.33% | 35.17% |
| Average Diluted Shares Outstanding | 65.15% | 84.08% | 74.29% | 61.33% | 35.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |